Status
Conditions
About
Background:
Objectives:
Eligibility:
Design:
Full description
AREDS2 is a multi-center, Phase III, randomized clinical trial designed to assess the effects of oral supplementation of high doses of macular xanthophylls (lutein and zeaxanthin) and/or omega-3 long-chain polyunsaturated fatty acids (LCPUFAs) as a treatment for age-related macular degeneration (AMD), cataract and moderate vision loss. In addition to this objective, the AREDS2 study will provide information on the clinical course, prognosis, and risk factors for development and progression of both AMD and cataract. Other study goals include the evaluation of eliminating beta-carotene and/or reducing zinc in the original AREDS formulation on the progression and development of AMD. AREDS2 will also seek to validate the fundus photographic AMD scale developed from AREDS.
The objective of this protocol is to have AREDS2 participants submit blood and saliva samples to the AREDS2 Genetic Repository (Fisher BioServices, Rockville, MD) in order to provide further materials for the study of the genetic and biochemical bases for eye disease and possibly other diseases.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Participants will be eligible if they were enrolled in the AREDS2 protocol and willing to have their blood drawn and saliva collected.
EXCLUSION CRITERIA:
Participants will not be eligible if they were not enrolled in AREDS2 and are not willing to have their blood drawn and saliva collected.
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal